News Ose-Immuno-HD Home > Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome > Ose-Immuno-HD 19 March 2020
